These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 18392823)

  • 1. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation.
    Zhu D; Corral LG; Fleming YW; Stein B
    Cancer Immunol Immunother; 2008 Dec; 57(12):1849-59. PubMed ID: 18392823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Properties of thalidomide and its analogues: implications for anticancer therapy.
    Teo SK
    AAPS J; 2005 Mar; 7(1):E14-9. PubMed ID: 16146335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model.
    Hernandez-Ilizaliturri FJ; Reddy N; Holkova B; Ottman E; Czuczman MS
    Clin Cancer Res; 2005 Aug; 11(16):5984-92. PubMed ID: 16115943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
    Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB
    Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo.
    Reddy N; Hernandez-Ilizaliturri FJ; Deeb G; Roth M; Vaughn M; Knight J; Wallace P; Czuczman MS
    Br J Haematol; 2008 Jan; 140(1):36-45. PubMed ID: 17995965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells.
    Acebes-Huerta A; Huergo-Zapico L; Gonzalez-Rodriguez AP; Fernandez-Guizan A; Payer AR; López-Soto A; Gonzalez S
    Biomed Res Int; 2014; 2014():265840. PubMed ID: 25313353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenalidomide down regulates the production of interferon-gamma and the expression of inhibitory cytotoxic receptors of human Natural Killer cells.
    Dauguet N; Fournié JJ; Poupot R; Poupot M
    Cell Immunol; 2010; 264(2):163-70. PubMed ID: 20621290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications.
    Tai YT; Li XF; Catley L; Coffey R; Breitkreutz I; Bae J; Song W; Podar K; Hideshima T; Chauhan D; Schlossman R; Richardson P; Treon SP; Grewal IS; Munshi NC; Anderson KC
    Cancer Res; 2005 Dec; 65(24):11712-20. PubMed ID: 16357183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFβ1.
    Xu Y; Sun J; Sheard MA; Tran HC; Wan Z; Liu WY; Asgharzadeh S; Sposto R; Wu HW; Seeger RC
    Cancer Immunol Immunother; 2013 Oct; 62(10):1637-48. PubMed ID: 23982484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo.
    Zhang L; Qian Z; Cai Z; Sun L; Wang H; Bartlett JB; Yi Q; Wang M
    Am J Hematol; 2009 Sep; 84(9):553-9. PubMed ID: 19565649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma.
    Gribben JG; Fowler N; Morschhauser F
    J Clin Oncol; 2015 Sep; 33(25):2803-11. PubMed ID: 26195701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired T and NK cell response of bone marrow and peripheral blood stem cell products to interleukin (IL)-2.
    Ozerol I; Ageitos A; Heimann DG; Talmadge JE
    Int J Immunopharmacol; 1999 Aug; 21(8):509-21. PubMed ID: 10458540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.
    Benson DM; Bakan CE; Zhang S; Collins SM; Liang J; Srivastava S; Hofmeister CC; Efebera Y; Andre P; Romagne F; Bléry M; Bonnafous C; Zhang J; Clever D; Caligiuri MA; Farag SS
    Blood; 2011 Dec; 118(24):6387-91. PubMed ID: 22031859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity.
    Hagner PR; Chiu H; Ortiz M; Apollonio B; Wang M; Couto S; Waldman MF; Flynt E; Ramsay AG; Trotter M; Gandhi AK; Chopra R; Thakurta A
    Br J Haematol; 2017 Nov; 179(3):399-409. PubMed ID: 28771673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities.
    Le Roy A; Prébet T; Castellano R; Goubard A; Riccardi F; Fauriat C; Granjeaud S; Benyamine A; Castanier C; Orlanducci F; Ben Amara A; Pont F; Fournié JJ; Collette Y; Mege JL; Vey N; Olive D
    Front Immunol; 2018; 9():977. PubMed ID: 29780393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro modulation of natural killer activity of human peripheral blood mononuclear cells against prostate tumor cell line.
    Sheikhi A; Saadati K; Salmani R; Yahaghi N; Sheikhi A; Siemens DR
    Immunopharmacol Immunotoxicol; 2011 Dec; 33(4):700-8. PubMed ID: 21425925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells.
    Galustian C; Meyer B; Labarthe MC; Dredge K; Klaschka D; Henry J; Todryk S; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB; Dalgleish AG
    Cancer Immunol Immunother; 2009 Jul; 58(7):1033-45. PubMed ID: 19009291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers.
    Wu L; Parton A; Lu L; Adams M; Schafer P; Bartlett JB
    Cancer Immunol Immunother; 2011 Jan; 60(1):61-73. PubMed ID: 20848094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of natural killer cell effector functions through lenalidomide/dasatinib and their combined effects against multiple myeloma cells.
    Jungkunz-Stier I; Zekl M; Stühmer T; Einsele H; Seggewiss-Bernhardt R
    Leuk Lymphoma; 2014 Jan; 55(1):168-76. PubMed ID: 23573828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of thalidomide and lenalidomide in mantle cell lymphoma.
    Richardson SJ; Eve HE; Copplestone JA; Dyer MJ; Rule SA
    Acta Haematol; 2010; 123(1):21-9. PubMed ID: 19907157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.